The company anticipates reporting topline results from the Phase III NEAT trial in the second half of next year.
Quince Therapeutics has dosed the first subject in its Phase III NEAT clinical trial of EryDex for the treatment of Ataxia-Telangiectasia (A-T), an inherited neurodegenerative and immunodeficiency disorder.
EryDex consists of dexamethasone sodium phosphate (DSP) encapsulated within the red blood cells of the patient.
The global, multicentre, double-blind, randomised, placebo-controlled trial will analyse the neurological effects of EryDex in A-T patients.
Conducted under a Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA), the trial aims to enrol approximately 86 subjects aged six to nine years (primary analysis population) and nearly 20 people aged ten years or above.
Trial subjects will be categorised into a 1:1 ratio to receive either EryDex or a placebo, with the treatment regimen involving six infusions given every 21 to 30 days.